Partners
Partners
Meet our partners
When joining the BII programs, start-ups become part of an international community focused on bringing ideas to life and science to the market.
In collaboration with our partners, we are looking to create value for the companies in BII’s programs and the ecosystem we are a part of. The partnerships are designed to support start-ups in their journey – and essentially increase the life science start-ups’ likelihood of success.
Meet our partners below and click on the read more button to find out more about what they offer start-ups in BII’s community.
University collaborations
DTU develops technology for people. With our international elite research and study programmes, we are helping to create a better world and to solve the global challenges formulated in the UN’s 17 Sustainable Development Goals. Hans Christian Ørsted founded DTU in 1829 with a clear vision to develop and create value using science and engineering to benefit society. That vision lives on today.
The University of Copenhagen was founded in 1479 by the Danish king Christian 1, and today has 37,500 students and 9,000 employees – of whom some 5,000 are researchers – and revenues of DKK 9.1 billion. Nine Nobel Prizes have been awarded to researchers at the University. The University of Copenhagen consistently ranks as the top university in Denmark and Scandinavia.
Read more at https://www.ku.dk/
Aarhus University (AU) is one of Denmark’s largest research and teaching hubs, with its main campus in downtown Aarhus. Rooted in strong disciplines, researchers and students have been generating new knowledge here for over 90 years. Aarhus University has 38,000 students, five faculties, research activities all over the country and campuses in Aarhus, Herning and Emdrup.
Research and education of the highest international quality are at the core of our mission, and strong partnerships with our society are at the heart of our activities. Thanks to our size and reputation as a leading research-intensive university, Aarhus University has strong impact and influence across the entire spectrum of disciplines, locally, nationally and globally.
Among more than 17,000 universities worldwide, Aarhus University is in the top 100 on several of the international rankings, and with its recently launched business collaboration and innovation initiative, Aarhus University will create even more tangible value for society.
Industry collaborations
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in St-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries, and markets its products in 110 countries.
Find more information about them here.
Ferring Pharmaceuticals is an Industrial Partner.
Program Advisory Group - Therapeutics
BII’s program advisory group / financing (VC) partnerships are focused on improving the likelihood of successful exists for our start-ups. The program advisory group of internationally-oriented VC companies are advising BII in the selection of start-ups for our programs.
Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Find more information about them here.
Novo Holdings is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Find more information about them here.
Sofinnova Partners is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
New Enterprise Associates (NEA) is a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play.
NEA is part of the Therapeutics Program Advisory Group.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies pursuing innovative science to significantly impact medical care. SR One’s team of investment professionals, located in the US and UK, have experience spanning basic science, drug development and commercialization. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. In its 30+ year history, SR One has invested >$1.1 billion in close to 190 companies, and its current portfolio includes 40+ private and public investments.
Find more information about them here‘
SR One is part of the Therapeutics Program Advisory Group.
Program Advisory Group - BioIndustrials
BII’s program advisory group / financing (VC) partnerships are focused on improving the likelihood of successful exists for our start-ups. The program advisory group of internationally-oriented VC companies are advising BII in the selection of start-ups for our programs.
Wellington Partners is a leading European Venture Capital firm investing in early – and growth stage life science companies. Wellington Partners is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totalling EUR 1 billion, and more than EUR 400 million committed to Life Sciences, Wellington Partners has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, Wellington Partners has invested in more than 40 innovative life science companies, including Actelion (acquired by J&J), Definiens (acquired by AZ/Medimmune), Invendo (acquired by Ambu), MTM laboratories (acquired by Roche), Rigontec (acquired by MSD), Symetis (acquired by Boston Scientific), Themis (acquired by MSD), Immatics and AMBOSS.
Wellington Partners is part of the BioIndustrial Program Advisory Group.
Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Find more information about them here.
Novo Holdings is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Find more information about them here.
Sofinnova Partners is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
The March Fund invests into biotechnology and data science at the interface of food, health and sustainability.
The March Fund is part of the BioIndustrial Program Advisory Group.
Program Advisory Group - Health Tech
BII’s program advisory group / financing (VC) partnerships are focused on improving the likelihood of successful exists for our start-ups. The program advisory group of internationally-oriented VC companies are advising BII in the selection of start-ups for our programs.
Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Find more information about them here.
Novo Holdings is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Find more information about them here.
Sofinnova Partners is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
BioVentures MedTech Funds invests in leading-edge medical technologies. Founded by the highly experienced team of BioVentures Investors, BioVentures MedTech Growth Capital Fund and BioVentures MedTech Innovation Fund target companies developing next-generation implantable and disposable devices, diagnostics, imaging, and digital health.
BioVentures Investors is part of the HealthTech Program Advisory Group.
Rock Health exists to fund and support entrepreneurs working at the intersection of healthcare and technology. Put simply, Rock Health’s mandate is impact. Rock Health want to make healthcare massively better for every human being—driving down the cost to deliver improved services to more people. Massively better means incredible change—it’s improvement by an order of magnitude or more along every dimension—healthcare that is incredibly functional, reliable, convenient, and yes, inexpensive. Learn more about Rock Health on: https://rockhealth.com/
Program Partners
BII’s business acceleration partnerships are focused on improving the journey of our start-ups by providing them with tools and expertise.
Back Bay’s expert guidance to companies at the earliest stages nourishes insight into the most promising science and technologies in development. They couple this with an exceptional understanding of development strategies globally, resulting in a true partnership for every stage of development.
Back Bay advisors and bankers bring their unique perspective through landscape analyses and patient journey, inflection points, capital raise planning, partnering, exit strategies, and much more. They can help figure out what to do and then get it done.
As an innovation-driven and customer-focused company, WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need.
Read more about WuXi AppTec here.
Coulter Partners is a board and senior level executive search specialist focused exclusively on global Life Sciences. From their offices in the UK, Europe, North America and Asia-Pacific, they work together across boundaries and disciplines to build outstanding leadership teams for their clients in the pharmaceuticals, biotechnology, medical devices, diagnostics, health tech, CRO and services sectors. Their industry leading reputation is founded on deep sector knowledge and innovative thinking. Their strategy is built on a unique team culture and true global reach.
“Our goal is to bring you the world’s best talent.”
Find more information about Coulter Partners here
Innovayt helps BII start-ups and researchers obtain funding for their projects through high-quality grant and funding applications. Innovayt offer a broad range of services, including: identification and selection of funding opportunities; preparation and writing of effective funding applications; assistance for project management after approval; and training and public speaking related to innovation and finance. In their work with innovation funding, Innovayt can assist BII start-ups throughout all phases of projects, from ideation through application and submission to project management.
Lyhne Life is specialized in communication for healthcare, medical, life sciences and biotech companies.
They work structured and agile with insights & strategy, creative development, implementation and activation. And they have no heavy and traditional apparatus, but instead a team of collaborating specialists with the skills required by the project.
They know that successful companies and strong brands need to evolve all the time – and they can help start-ups drive the development that creates positive change through communication.
HØIBERG is a full service patent law firm providing services within Intellectual Property Rights (IPR), including Patents, Designs, Innovation Management, and Business Development. They provide expert IPR knowledge in fields ranging from biotech, foodtech, medtech, nanotech, chemistry and cleantech to hightech. They assist BII projects and start-ups at every stage of development – from idea to realization.
Plesner Law Firm is a contributing partner in the BII network and offers the BII start-ups free legal advice and expertise to avoid the many legal pitfalls that entrepreneurs face when starting a business. As part of the partnership, two lawyers from Plesner are present one day a week at the BII offices where they will provide consultancy and legal guidance.
Zacco is a full-service intellectual property consultancy and contributing partner in the BII network. Zacco offers BII start-ups free advice and expertise on intellectual property rights to avoid legal pitfalls and to strengthen their position when looking for investors or cooperation partners.